1:00 PM – 2:30 PM – EDT, April 20, 2021 This 90-minute webinar in eligible in most states for 1.5 CLE credits. Presented by Strafford Register Here Why You Should Attend This CLE webinar will analyze down-round financings from the vantage point of the company and its investors. The panel will discuss the implications of a…

Date & Time May 31st, 2019, 10am Why You Should Attend Rimon’s FinTech Partner, Dror Futter, will be speaking at Princeton Entrepreneurship Council’s “Startup Workshop: Legal Considerations for Startups. Register here Dror Futter is a partner in the Rimon, PC law firm. Dror’s practice focuses on representing startup companies in their financing and merger and acquisition transactions and…

Tokens, security tokens, cryptocurrency, or however you wish to define the digital asset which distributed ledger technology has now allowed us to pull from ether, puts issuers and exchangers of this value within the cross-hairs of both Federal and State money transmitter regulation. The question becomes then whether token-driven blockchain businesses that mint and sell…

Two Rimon Partners will be presenting at the upcoming Legaltech West Coast conference, to take place on July 13-14, 2015 in San Francisco, CA. LegalTech is a premier legal technology conference hosted by ALM Media. John Isaza, FAI, will participate in a panel titled “The New Big Bang: 21st Century Information Governance Challenges”. The panel…

So how do biotech ventures govern themselves to run efficiently while complying with state corporate law statutes and state and federal securities laws and regulations imposed by stock exchanges? Frugality that is often self-imposed by scientific founders and then endorsed by the angel investors and venture capital company investors that follow sequentially tend to result…

The public securities markets and the underwriters that lead biotech companies into them dictate a common capital structure suitable for IPOs, which structure almost always deviates starkly from the capital structure of the venture at inception and during its growth phase. Startups frequently commence corporate life structured as limited liability companies with a few founders…

Mindful that this series of articles describes biotech ventures that are ripe for initial public offerings even before launching an income-producing drug product into the commercial market, the paramount objective for all such ventures is to manufacture drugs and commence marketing, sales and distribution thereof as soon as possible. As you read in the previous…

For a drug discovery start-up, patent protection of the intellectual property underlying the commercialization pursuit is critically important. If the company is a university or research institution spin-out that obtained licensed rights to intellectual property through a technology transfer, either the licensor or the licensee – as set forth in the License Agreement — must pursue…

The U.S. Food & Drug Administration regulates new drug approvals in a process that is extremely thorough, lengthy and expensive. Regulations apply to a drug candidate’s product development phase, the approval process and after approval. Failure to comply could have serious business and financial con-sequences to a biotech venture, including the FDA’s refusal to approve…

Many biotech ventures begin life as an invention conceived by a scientist/professor working in a laboratory at a federally-funded university or scientific institute. The intellectual property underlying such inventions is owned by the academic institution, a potentially valuable asset to be nurtured. Since enactment of the Bayh-Dole Act in 1980, academic institutions through their technology…